<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>HELIXMITH</title>
    <link type="text/css" rel="stylesheet" href="css/reset.css"/>
    <link type="text/css" rel="stylesheet" href="css/style.css"/>
    <link type="text/css" rel="stylesheet" href="css/animate.css"/>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>
<body>
<!--wrapper-->
<div class="wrapper">
    <!--headNavigation-->
    <div class="headNavigation headImage3 wow fadeIn">
        <!--inside-->
        <div class="inside">
            <!--menus-->
            <div class="menus">
                <!--logo-->
                <div class="left">
                    <a href="index.html">
                        <img src="img/logo.svg">
                    </a>
                </div>
                <!--//logo-->
                <div class="right">
                    <ul class="pc">
                        <li>
                            <a href="about_1.html">
                                About Us
                            </a>
                            <div class="dropdown-content">
                                <div class="box">
                                    <a href="about_1.html">
                                        <p>
                                            About Us
                                        </p>
                                    </a>
                                    <a href="about_2.html">
                                        <p>
                                            Team Member
                                        </p>
                                    </a>
                                    <a href="about_3.html">
                                        <p>
                                            Contact
                                        </p>
                                    </a>
                                </div>
                            </div>
                        </li>
                        <li>
                            <a href="vm202.html">
                                VM202
                            </a>
                            <div class="dropdown-content">
                                <div class="box">
                                    <a href="vm202.html#first">
                                        <p>
                                            VM202
                                        </p>
                                    </a>
                                    <a href="vm202.html#second">
                                        <p>
                                            VM202 Clinical Programs
                                        </p>
                                    </a>
                                    <a href="vm202_dpn.html">
                                        <p>
                                            Engensis in DPN
                                        </p>
                                    </a>
                                </div>
                            </div>
                        </li>
                        <li>
                            <a href="platform.html">
                                Early Phase Programs
                            </a>
                            <div class="dropdown-content">
                                <div class="box">
                                    <a href="platform.html#first">
                                        <p>
                                            Neuromyon
                                        </p>
                                    </a>
                                    <a href="platform.html#second">
                                        <p>
                                            Chimericsmith
                                        </p>
                                    </a>
                                    <a href="platform.html#second">
                                        <p>
                                            Oncosmith
                                        </p>
                                    </a>
                                </div>
                            </div>
                        </li>
                        <li>
                            <a href="botanicals.html">
                                Botanicals
                            </a>
                        </li>
                        <li>
                            <a href="about_3.html">
                                News
                            </a>
                            <div class="dropdown-content">
                                <div class="box">
                                    <a href="#">
                                        <p>
                                            Contact
                                        </p>
                                    </a>
                                </div>
                            </div>
                        </li>
                    </ul>
                    <ul class="mobile displayFlex">
                        <li>
                            <img src="img/mobile_menu_ico.svg" id="showPanel"/>
                        </li>
                    </ul>
                </div>
            </div>
            <!--//menus-->
            <!--content-->
            <div class="content subContent">
                <h1 class="headText">
                    Engensis (VM202) Overview
                </h1>
            </div>
            <!--//content-->
        </div>
        <!--//inside-->
    </div>
    <!--//headNavigation-->
    <!--1-->
    <div class="vm202Section marginTop50" id="first">
        <div class="first">
            <!--text-->
            <div class="text wow fadeIn">
                <h1 class="headText">
                    Engensis (VM202)
                </h1>
                <p>
                    Engensis (VM202) is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte
                    growth factor (HGF), a protein well known to induce 1) new microvasculature formation, 2) nerve cell
                    regeneration, 3) amelioration of atrophic condition, and 4) suppression of pain-related factors.
                </p>
                <p>
                    Engensis is designed to simultaneously express two isoforms (HGF723 and HGF 728) efficiently,
                    without changing the coding region of the gene. Due to this nature of Engensis, multiple clinical
                    studies have shown excellent efficacy and safety.
                </p>
            </div>
            <!--//text-->
            <!--image-->
            <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                <img src="img/vm202_img1_pc.svg" class="pc"/>
                <img src="img/vm202_img1_mobile.svg" class="mobile"/>
            </div>
            <!--//image-->
            <!--text-->
            <div class="text wow fadeIn" data-wow-delay=".4s">
                <p>
                    Currently, Engensis clinical programs have advanced in the US as follows:
                    - Diabetic peripheral neuropathy (DPN): US phase III trial ongoing, 25 sites and 500+ subjects
                    enrolled, expected to complete and announce results in 2019<br>
                    - Diabetic foot ulcer (DFU): US phase III trial ongoing, 28 sites and 300+ subjects planned<br>
                    - Amyotrophic lateral sclerosis (ALS): Positive trends on efficacy and safety observed from US
                    phase I trial, US phase II trial planned to start in 2019<br>
                    - Coronary artery disease (CAD): Positive trends on efficacy and safety observed from Korea phase I
                    trial
                </p>
                <p>
                    VM202 is the only plasmid DNA-based biopharmaceutical that simultaneously produces high levels of
                    two isoforms of hepatocyte growth factor—HGF728 and HGF723. The simultaneously expressed both
                    isoforms of HGF then bind to the c-Met receptor, inducing multiple bioactivities that include the
                    formation of new blood vessels, nerve regeneration, suppression of pain-related factors, and
                    amelioration of amytrophic condition.
                </p>
                <p>
                    Phase III clinical trials using VM202 are currently underway in the United States for diabetic
                    peripheral neuropathy and chronic diabetic foot ulcer, and phase II studies for amyotrophic lateral
                    sclerosis and myocardial infarction are in preparation.
                </p>
            </div>
            <!--//text-->
        </div>
    </div>
    <!--//1-->
    <!--divider-->
    <div class="divider"></div>
    <!--//divider-->
    <!--2-->
    <div class="vm202Section marginTop50" id="second">
        <div class="first">
            <!--text-->
            <div class="text wow fadeIn">
                <h1 class="headText">
                    VM202 Clinical Programs
                </h1>
            </div>
            <!--//text-->
            <!--image-->
            <div class="vm202Table wow fadeIn" data-wow-delay=".2s">
                <img src="img/vm202_img2_pc.svg" class="pc"/>
                <img src="img/vm202_img2_mobile.svg" class="mobile"/>
            </div>
            <!--//image-->
        </div>
    </div>
    <!--//2-->
    <!--divider-->
    <div class="divider"></div>
    <!--//divider-->
    <!--3-->
    <div class="vm202Section marginTop50" id="second">
        <div class="first">
            <!--text-->
            <div class="text wow fadeIn">
                <h1 class="headText">
                    Publications on Engensis (VM202)
                </h1>
            </div>
            <!--//text-->
            <!--text-->
            <div class="text wow fadeIn">
                <!--head-->
                <div class="head">
                    <h1>
                        Expression vector pCK and therapeutic gene HGF
                    </h1>
                </div>
                <!--//head-->
                <p>
                    1. Lee et al., Improved expression of vascular endothelial growth factor by naked DNA in mouse
                    skeletal muscles: implication for gene therapy of ischemic diseases. Biochemical and Biophysical
                    Research Communications, 2000;272:230-235
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=Improved%20Expression%20of%20Vascular%20Endothelial%20Growth%20Factor%20by%20Naked%20DNA%20in%20Mouse%20Skeletal%20Muscles"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    2. Pyun et al., Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral
                    artery augmentation in a rabbit model of limb ischemia. Gene Therapy, 2010;17:1442-1452.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=20668482" target="_blank">
                        Click here
                    </a>
                </p>
            </div>
            <!--//text-->
            <!--text-->
            <div class="text wow fadeIn">
                <!--head-->
                <div class="head">
                    <h1>
                        Preclinical
                    </h1>
                </div>
                <!--//head-->
                <p>
                    3. Carlsson et al., Quantitative MR measurements of regional and global left ventricular function
                    and
                    strain after intramyocardial transfer of VM202 into infarcted swine myocardium. American Journal of
                    Physiology - Heart and Circulatory Physiology, 2008;295(2):H522-H532.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=18539758"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    4. Cho et al., Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte
                    growth factor in a porcine acute myocardial infarction model. European Journal of Cardio-thoracic
                    Surgery, 2008;34:857-863.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=18620865" target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    5. Saeed et al., MR assessment of myocardial perfusion, viability, and function after
                    intramyocardial transfer of VM202, a new plasmid human hepatocyte growth factor in ischemic swine
                    myocardium. Radiology, 2008;249:107-118.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=18682582"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    6. Saeed et al., Cardiovascular magnetic resonance imaging in delivering and evaluating the efficacy
                    of hepatocyte growth factor gene in chronic infarct scar. Cardiovascular Revascularization
                    Medicine, 2011;12:111-122.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=21421190" target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    7. Perin et al., Human hepatocyte growth factor (VM202) gene therapy via transendocardial injection
                    in a pig model of chronic myocardial ischemia. Journal of Cardiac Failure, 2011;17:601-611.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=21703533"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    8. Hahn et al., Enhanced cardio-protective effects by coexpression of two isoforms of hepatocyte
                    growth factor from naked plasmid DNA in a rat ischemic heart disease model. The Journal of Gene
                    Medicine, 2011;13:549-555.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=21898720" target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    9. Nho et al., Effective control of neuropathic pain by transient expression of hepatocyte growth
                    factor in a mouse chronic constriction injury model. The FASEB Journal, 2018; 32(9): 5119–5131
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Effective+control+of+neuropathic+pain+by+transient+expression+of+hepatocyte+growth+factor+in+a+mouse+chronic+constriction+injury+model"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    10. Ko et al., Hepatocyte Growth Factor (HGF) Promotes Peripheral Nerve Regeneration by Activating
                    Repair Schwann Cells. A naturesearch journal, 2018;8(1):8316
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973939/" target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    11. Choi et al., Hepatocyte Growth Factor Regulates the miR-206-HDAC4 Cascade to Control Neurogenic
                    Muscle Atrophy following Surgical Denervation in Mice. Molecular Therapy-Nucleic Acids, 2018;
                    12;568-577.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(18)30140-9"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    12. Ko et al., Ko et al., c-Fos is necessary for HGF-mediated gene regulation and cell migration in
                    Schwann cells. Biochemical and Biophysical Research Communications, 2018;18;503(4):2855-2860.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.sciencedirect.com/science/article/pii/S0006291X18317364?via%3Dihub"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    13. Lee et al., Disproportionately high levels of HGF induce the degradation of the c-met receptor
                    through the proteasomal degradation pathway, Biochemical and Biophysical Research
                    Communications, 2018;2;505(3):925-930.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.sciencedirect.com/science/article/pii/S0006291X18320631"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    14. W.S Choi et al., Hepatocyte growth factor regulates miR-206-HDAC4 cascade to control the
                    neurogenic muscle atrophy following surgical denervation in mice. Molecular Therapy-Nucleic Acids,
                    2018;12:568-577
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077135/"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    15. Ko et al., c-Fos is necessary for HGF-mediated gene regulation and cell migration in Schwann
                    cells, Biochem Biophys Res Commun., 2018;503(4):2855-2860
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/30103949"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    16. Lee et al., Disproportionately high levels of HGF induce the degradation of the cmet receptor
                    through the proteasomal degradation pathway. Biochem Biophys Res Commun., 2018;505(3):925-930
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/30309648"
                       target="_blank">
                        Click here
                    </a>
                </p>
            </div>
            <!--//text-->
            <!--text-->
            <div class="text wow fadeIn">
                <!--head-->
                <div class="head">
                    <h1>
                        Clinical
                    </h1>
                </div>
                <!--//head-->
                <p>
                    <b>17. VM202-PAD (Critical Limb Ischemia)</b><br>
                    Henry et al., Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor
                    in critical limb ischemia patients: a phase I study. Gene Therapy, 2011;18:788-794.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=21430785"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    <b>18. VM202-PAD (Critical Limb Ischemia)</b><br>
                    Gu et al., A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor
                    to treat patients with critical limb ischemia. The Journal of Gene Medicine, 2011;13:602-610.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed?term=A%20phase%20I%20clinical%20study%20of%20naked%20DNA%20expressing%20two%20isoforms%20of%20hepatocyte%20growth%20factor%20to%20treat%20patients%20with%20critical%20limb%20ischemia"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    <b>19. VM202-CAD (Ischemic Heart Disease)</b><br>
                    Kim et al., Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I
                    clinical study. Gene Therapy, 2013;20:717-722.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Intramyocardial+transfer+of+hepatocyte+growth+factor+as+an+adjunct+to+CABG:+phase+I+clinical+study"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    <b>20. VM202-DPN (Diabetic Peripheral Neuropathy)</b><br>
                    Ajroud‐Driss et al., Phase 1/2 open-label dose-escalation study of plasmid DNA expressing hepatocyte
                    growth factor in patients with painful diabetic neuropathy. Molecular Therapy, 2013;21:1279-1286.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Phase+1/2+Open-Label+Dose-Escalation+Study+of+Plasmid+DNA+Expressing+Hepatocyte+Growth+Factor+in+Patients+with+Painful+Diabetic+Neuropathy"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    <b>21. VM202-DPN (Diabetic Peripheral Neuropathy)</b><br>
                    Kessler et al., Double-blind, placebo-controlled study of HGF gene therapy in diabetic
                    neuropathy. Annals of Clinical and Translational Neurology, 2015;2:465-478.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Double-blind,+placebo-controlled+study+of+HGF+gene+therapy+in+diabetic+neuropathy"
                       target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    <b>22. VM202-PAD (Critical Limb Ischemia)</b><br>
                    Kibbe et al., Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor
                    in patients with critical limb ischemia. Gene Therapy, 2016;3:306-312.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/26649448" target="_blank">
                        Click here
                    </a>
                </p>
                <p>
                    <b>23. VM202-ALS (Amyotrophic Lateral Sclerosis)</b><br>
                    Robert L. Sufit et al., Open label study to assess the safety of VM202 in subjects with amyotrophic
                    lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017
                    May;18(3-4):269-278.
                </p>
                <p>
                    <span class="fontBold">External Link:</span><br>
                    <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Open+label+study+to+assess+the+safety+of+VM202+in+subjects+with+amyotrophic+lateral+sclerosis"
                       target="_blank">
                        Click here
                    </a>
                </p>
            </div>
            <!--//text-->
        </div>
    </div>
    <!--//3-->
    <!--divider-->
    <div class="divider"></div>
    <!--//divider-->
    <!--footer-->
    <div class="footer">
        <div class="menus">
            <a href="#">
                Privacy Policy
            </a>
            /
            <a href="careers.html">
                Careers
            </a>
        </div>
        <div class="info">
            <div class="left">
                5th Fl. Bldg. 203 Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 00826, Republic of Korea<br>
                Tel. 82.2.2102.7200 / Fax. 82.2.873.8022 / Email. hxir@helixmith.com
            </div>
            <div class="right">
                Copyright © 2019 Helixmith Co., Ltd. All Rights Reserved.
            </div>
        </div>
    </div>
    <!--//footer-->
</div>
<!--//wrapper-->
<!--mobile Menu-->
<div id="mobileMenu">
    <ul>
        <li>
            <a href="about_1.html">
                About Us
            </a>
        </li>
        <li>
            <a href="about_2.html">
                Team Member
            </a>
        </li>
        <li>
            <a href="about_2.html">
                Locations
            </a>
        </li>
        <li>
            <a href="vm202.html">
                VM202
            </a>
        </li>
        <li>
            <a href="vm202.html">
                Engensis in DPN
            </a>
        </li>
        <li>
            <a href="platform.html">
                Platform & Technology
            </a>
        </li>
        <li>
            <a href="botanicals.html">
                Botanicals
            </a>
        </li>
        <li>
            <a href="about_3.html">
                News
            </a>
        </li>
        <li>
            <a href="about_3.html">
                Contact
            </a>
        </li>
        <li>
            <a href="about_3.html">
                Careers
            </a>
        </li>
        <li>
            <div class="button" id="hidePanel">
                <img src="img/close_ico.svg"/>
            </div>
        </li>
    </ul>
</div>
<!--//mobile Menu-->
<!--js-->
<script src="js/wow.js"></script>
<script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>

<script>
    wow = new WOW(
        {
            animateClass: 'animated',
            offset: 100,
            callback: function (box) {
                console.log("WOW: animating <" + box.tagName.toLowerCase() + ">")
            }
        }
    );
    wow.init();

    $(document).ready(function () {

        $("#showPanel").click(function () {
            $("#mobileMenu").show();
        });

        $("#hidePanel").click(function () {
            $("#mobileMenu").hide();
        });

    });
</script>
<!--//js-->
</body>
</html>